Patient characteristics were well balanced in the study, with no significant differences in baseline lab values, comorbidities, and demographics. There were 4,488 patients in the chlorhexidine group and 4,852 in the control group. In both, 60% were men, the median age was almost 60 years old, and respiratory and cardiovascular complications were the most common reasons for ICU admission.
A previous study reported that chlorhexidine bathing significantly reduced ICU acquisition of multidrug-resistant organisms and health care–associated bloodstream infections. The study also included bone marrow transplant patients, who have a greater risk of infection, and the wipes were used for 6 months instead of periods of 10 weeks. The company that makes the wipes paid in part for the study (N. Engl. J. Med. 2013;368:533-542).
“It is possible that a longer intervention may have ecological consequences that reduce infectious outcomes,” but “the reduction in health care–associated bloodstream infections ... was driven primarily by a reduction in positive blood culture results caused by ... skin commensal coagulase-negative staphylococci, and it is not clear if this observation was a result of blood culture contamination or true infection,” Dr. Noto and his team said.
Dr. Noto reported no disclosures. One author reported that his spouse receives research funding from Gilead, MedImmune, and SanofiPasteur and is an advisor for Teva. The work was funded by the National Institutes of Health and Vanderbilt.